Emerging drugs for acute graft-versus-host disease.
The number of allogeneic hematopoietic cell transplantations (HCT) continues to increase. More than 15,000 allogeneic transplantations are performed annually. The graft-versus-leukemia/tumor effect during allogeneic HCT effectively eradicates many hematological malignancies. The development of novel strategies that use donor leukocyte infusions, nonmyeloablative conditioning and umbilical cord blood transplantation have helped expand the indications for allogeneic HCT over the past several years, especially among older patients. Yet the major complication of allogeneic HCT, graft-versus-host disease, remains lethal and limits wider application of allogeneic HCT. In this article, we review current practice and recent advances made in prevention and treatment of graft-versus-host disease.
Khaled
Yasser
Y
The University of Michigan, 1500 East Medical Center Drive, SPC 5942, 6310 Comprehensive Cancer Center, Ann Arbor, MI 48109-0942, USA.
Reddy
Pavan
P
Krijanovski
Oleg
O
D000208:Acute Disease; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016879:Salvage Therapy / Q000639:trends; D014184:Transplantation, Homologous / Q000009:adverse effects*
D015507:Drugs, Investigational